Last updated: 2026-10-13 02:00:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
MetaVia Inc. (MTVA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.45, with a market capitalisation of $9.29M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.97 to $14.85. This page covers its latest market performance, valuation, price trends and company information.
$9.29M | |
$1.43 | |
$30.25 | |
$0.97 | |
$1.41 | |
135.62K | |
91.14K | |
-- | |
$14.85 | |
$0.97 | |
-- | |
-- |
MetaVia Inc. (MTVA) last closed at $1.41 as of 2026-10-12 23:33:00, unchanged from the previous close of $1.41.
During the latest regular trading session, MTVA traded between $0.97 and $30.25, with a volume of 135.62K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, MetaVia Inc. (MTVA) moved from $1.54 to $1.45, representing a decline of 5.91% ($0.09).
The stock traded between $1.33 and $1.65 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 63.94 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 3.5%
MTVA is currently trading at $1.45, placing it 3.5% of the way from its 52-week low of $0.97 to its 52-week high of $14.85. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MetaVia Inc. (MTVA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.